サンプル依頼リスト カート
  • English
  • Korean
表紙：糖尿病性ケトアシドーシスの世界市場-2023年～2030年
市場調査レポート
商品コード
1345409

糖尿病性ケトアシドーシスの世界市場-2023年～2030年

Global Diabetic Ketoacidosis Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
糖尿病性ケトアシドーシスの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の糖尿病性ケトアシドーシス市場は2022年に15億米ドルに達し、2023-2030年の予測期間中にCAGR 5.8%で成長し、2030年には23億米ドルに達すると予測されています。

糖尿病性ケトアシドーシス（DKA）市場動向は、技術的進歩や研究調査の高まりにより、調査件数が増加しています。糖尿病性ケトアシドーシスの治療のために、いくつかのインスリンや他の治療法が発売されています。また、成人だけでなく小児の糖尿病性ケトアシドーシスの管理にも補液療法が利用されています。

さらに、承認された電解質補充療法の利用可能性の上昇による糖尿病性ケトアシドーシスの治療件数の増加や、市場における糖尿病性ケトアシドーシス症例数の増加、および研究開発の増加が糖尿病性ケトアシドーシス市場規模を押し上げています。

同市場は、この分野における進歩の高まりの結果、北米地域からの治療需要が伸びています。Novo Nordisk A/S、Baxter Healthcare Corporation、B. Braun Medical Inc.、Merit Pharmaceuticalのような主要企業が市場で積極的に活動しているため、市場は今後成長するでしょう。

ダイナミクス

研究者の研究開発が糖尿病性ケトアシドーシス市場の成長を牽引

コルチゾール、グルカゴン、成長ホルモン、アドレナリンの増加とともに、絶対的または相対的なインスリン欠乏が糖尿病性ケトアシドーシスの通常の原因です。このインスリン不足によって引き起こされる肝糖新生、脂肪分解、グリコーゲン分解の亢進により、重度の高血糖、ケトアシドーシス、ケトン尿が生じます。循環量や組織灌流の改善、血清グルコースや浸透圧の漸減、電解質不均衡の是正、併存する誘発因子の同定と迅速な治療などが、高血糖クリーゼ患者の治療目標です。

DKAの治療を成功させるためには、臨床検査値および臨床測定値を用いて、前述の目標に関連した患者の頻繁なモニタリングが必要です。ほとんどの症例では、基礎感染、インスリン投与ミス、以前は知られていなかった糖尿病、手術によるストレスなどの誘因があります。

患者の予後を改善するには、早期の診断と治療が重要です。輸液蘇生、高血糖に対処するためのインスリン投与、アシドーシスの是正、電解質不均衡の是正、基礎的な原因や前駆症状の治療などが、すべて治療過程に含まれます。十分な治療を受けた患者の予後は非常に良好です。

糖尿病性ケトアシドーシスの有病率の上昇が市場成長に寄与する可能性

1型糖尿病のように持続的なインスリン分泌不全がもたらす最も深刻な代謝障害が、糖尿病性ケトアシドーシスです。糖尿病性ケトアシドーシスと呼ばれる生命を脅かす病気は、発見が遅すぎることが多いです。その影響（主に神経学的）を避けるためには、早期の診断が必要です。リグーリア州では、シャットダウン前と比較して、新たに糖尿病と診断された子供や青少年における糖尿病性ケトアシドーシスの発生率の上昇が観察されています。

2022年、米国国立衛生研究所の研究者は、1型糖尿病T1D（54.3％男性、平均年齢9.5 4.3歳）の3062の新しいケースを発見し、そのうち1347（44％）がDKAを発症しました。COVID-19の前後でDKAの有病率はかなり上昇した（37.5％-49.4％、p 0.0001）。中等度（＋5.4％）と重度（＋3.4％）のDKAの割合が劇的に増加しました。

この増加は、ロックダウンによって医療サービスへのアクセスが制限された後、診断が下されるまでの時間が長くなったことが原因かもしれません。ケトアシドーシスの危険性について、地域社会や医療関係者の啓発活動を通じて、より多くの知識を得ることは有益だと言えます。

糖尿病性ケトアシドーシス治療に伴う合併症が市場の成長を妨げる

低血糖は、インスリンが糖の細胞への侵入を許し、血糖値を低下させることで生じます。低血糖は、血糖値の低下が早すぎるために起こることがあります。糖尿病性ケトアシドーシスの治療に必要な輸液とインスリンの結果、カリウム値が低くなりすぎたり、低カリウム血症になったりすることがあります。心臓、筋肉、神経はすべて、カリウム値の低下によって影響を受ける可能性があります。

糖尿病性ケトアシドーシスの治療の一環として、カリウムと他のミネラルは、通常、これを防ぐために補液とともに投与されます。血糖値の急激な変化により、脳が腫れる脳浮腫が起こることがあります。特に糖尿病と診断されたばかりの小児は、この症状を経験する頻度が高いようです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究者による研究開発の成長
      • 糖尿病性ケトアシドーシスの有病率の上昇
    • 抑制要因
      • 糖尿病性ケトアシドーシス治療に伴う合併症
    • 機会
      • 政府およびNGOによる戦略的イニシアチブの高まり
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 小児糖尿病性ケトアシドーシス
  • 成人糖尿病性ケトアシドーシス

第8章 治療法別

  • インスリン療法
  • 電解質補充
    • カリウム
    • マグネシウム
    • 重炭酸塩
    • リン酸塩
  • 補液

第9章 エンドユーザー別

  • 病院
  • 学術・研究機関
  • 専門クリニック

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Novo Nordisk A/S
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Baxter Healthcare Corporation
  • B. Braun Medical Inc.
  • ICU Medical, Inc.
  • Pfizer Inc.
  • Merit Pharmaceutical
  • SteriCare Solutions
  • Soxa Formulations & Research（Pvt.）Ltd
  • BD
  • Fresenius Kabi USA

第13章 付録

目次
Product Code: PH6776

Overview

The global diabetic ketoacidosis market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.3 billion by 2030 growing with a CAGR of 5.8% during the forecast period 2023-2030.

The diabetic ketoacidosis (DKA) market trends show rising research owing to the rising technological advancements and research studies. Several insulin and other therapies are being launched for the treatment of diabetic ketoacidosis. Fluid replacement treatments are also utilized for management of diabetic ketoacidosis in pediatrics as well as adults.

Furthermore, rising treatment for diabetic ketoacidosis due to the rising availability of approved electrolyte replacement therapy and increase in the number of diabetic ketoacidosis cases in the market, and an increase in the research and development is driving up the diabetic ketoacidosis market size.

The market is experiencing a growth in demand for treatment from North America areas as a result of the rising advancements in this field. With significant competitors like Novo Nordisk A/S, Baxter Healthcare Corporation, B. Braun Medical Inc., and Merit Pharmaceutical actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by the Researchers Drive the Growth of the Diabetic Ketoacidosis Market

Absolute or relative insulin deficiency, together with an increase in cortisol, glucagon, growth hormone, and adrenaline, are the usual causes of diabetic ketoacidosis. Due to the increased hepatic gluconeogenesis, lipolysis and glycogenolysis caused by this insulin shortage, severe hyperglycemia, ketoacidosis, and ketonuria result. Improvements in circulatory volume or tissue perfusion, a gradual decrease in serum glucose as well as osmolality, correction of electrolyte imbalance, and identification and quick treatment of co-morbid triggering factors are among the therapy objectives for patients with hyperglycemic crises.

Frequent patient monitoring with relation to the aforementioned objectives using laboratory and clinical measurements is necessary for DKA treatment to be successful. In the majority of cases, there are triggering causes, such as an underlying infection, a missed insulin dose, diabetes that was not previously known, surgical stress, etc.

Improved patient outcomes depend on early diagnosis and treatment. Fluid resuscitation, insulin administration to address hyperglycemia, correction of acidosis, correction of electrolyte imbalances, and therapy of underlying causes or precipitants are all included in the course of treatment. Patients who receive sufficient care have a very good prognosis.

Rising Prevalence of Diabetic Ketoacidosis may Help in the Growth of the Market

The most serious metabolic disturbance brought on by sustained insulin insufficiency, as in type 1 diabetes, is diabetic ketoacidosis. A life-threatening illness called diabetic ketoacidosis is frequently detected too late. It requires an early diagnosis to avoid its effects, primarily neurological. In the Liguria Region, compared to years before to the shutdown, a rise in the incidence of diabetic ketoacidosis in newly diagnosed children and adolescents has been observed.

In 2022, researchers from the National Institutes of Health discovered 3062 new cases of Type 1 Diabetes T1D (54.3% males, mean age 9.5 4.3 years old), of which 1347 (44%) developed DKA. We saw a considerable rise in the prevalence of DKA between the pre- and post-COVID-19 periods (37.5%-49.4%, p .0001). The percentage of instances with moderate (+5.4%) and serious (+3.4%) DKA dramatically rose.

This rise may have been brought on by the longer time it took for a diagnosis to be made after the lockdown's restrictions decreased access to medical services. It would be beneficial to have more knowledge on the dangers of ketoacidosis through community and medical awareness initiatives.

Complications Associated with the Diabetic Ketoacidosis Treatment will Hamper the Growth of the Market

Hypoglycemia, commonly referred to as low blood sugar, occurs when insulin permits sugar to enter cells, which lowers blood sugar levels. Low blood sugar can result from a decline in blood sugar that occurs too quickly. The potassium level can go too low, or develop hypokalemia, as a result of the fluids and insulin required to treat diabetic ketoacidosis. The heart, muscles, and nerves can all be impacted by low potassium levels.

As an element of the treatment for diabetic ketoacidosis, potassium along with other minerals are typically given together with fluid replacement to prevent this. A rapid change in blood sugar level can result in cerebral edema, a swelling of the brain. Children seem to experience this more frequently, particularly those who have just been diagnosed with diabetes.

Segment Analysis

The global diabetic ketoacidosis market is segmented based on type, treatment and end user.

Owing to High Utilization, the Insulin Therap from Treatment Segment Accounted for Approximately 45.4% of the Diabetic Ketoacidosis Market Share

The death rate for DKA has dramatically dropped to 1% with the introduction of insulin and antibiotics. The standard of therapy is continuous intravenous insulin infusion. An early bolus of 0.1 U/kg followed by an infusion of 0.1 U/kg/h was advised by previous therapy guidelines. A current prospective randomized trial showed that individuals receiving hourly insulin infusions at 0.14 U/kg/hr do not require a bolus.

If the patient already has an anion gap when the plasma glucose level reaches 200-250 mg/dl, dextrose-containing drinks should be started, and the insulin rate of infusion may need to be decreased. According to numerous studies, treating adult patients with simple, mild diabetic ketoacidosis with subcutaneous insulin lispro per hour in a non-intensive medical facility may be safe and more affordable than treating such patients with intravenous normal insulin in an intensive care setting.

Patients who have never used insulin should start on a multi-dose insulin regimen at a dosage of 0.5 to 0.8 U/kg/day. Before ceasing the insulin drip, blood sugar should be checked again and the full metabolic profile completed in order to prevent the return of ketoacidosis during the transition phase. Insulin infusion must continue for 2 hours following the commencement of subcutaneous insulin.

Geographical Penetration

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for diabetic ketoacidosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand of treatment for diabetic ketoacidosis.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of infectious disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of diabetic ketoacidosis market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various treatment such as insulin therapy for intravenous usage for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the diabetic ketoacidosis market include: Novo Nordisk A/S, Baxter Healthcare Corporation, B. Braun Medical Inc., ICU Medical, Inc., Pfizer Inc., Merit Pharmaceutical, SteriCare Solutions, Soxa Formulations & Research(Pvt.) Ltd, BD and Fresenius Kabi USA among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide diabetic ketoacidosis market. The growth of the global diabetic ketoacidosis market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

  • Pediatric Diabetic Ketoacidosis
  • Adult Diabetic Ketoacidosis

By Treatment

  • Insulin Therapy
  • Electrolyte Replacement
    • Potassium
    • Magnesium
    • Bicarbonate
    • Phosphate
  • Fluid Replacement

By End User

  • Hospitals
  • Academic & Research Institutes
  • Specialty Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On May 10, 2022, new research from a real-world study by Joseph Bledsoe, MD and his colleagues of Intermountain Medical Center, found that using balanced crystalloids like lactated Ringer instead of saline solution reduces the risk of major adverse kidney events (MAKEs). For intravenous isotonic crystalloid infusion, common options are balanced crystalloids and ordinary 0.9% saline solution. Both are inexpensive and generally accessible.
  • On January 5, 2023, Spinnaker International LLC, BPGC Management LP, and R Investments now own the majority of Nurse Assist LLC, the company that produces medical water products under the Stericare Solutions name. With a concentration on USP sterile water and saline, prefilled flush syringes, and sterile saline wound flush and irrigation kits, Stericare is an independent specialist manufacturer of medical grade saline and water products.

Why Purchase the Report?

  • To visualize the global diabetic ketoacidosis market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of diabetic ketoacidosis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global diabetic ketoacidosis market report would provide approximately 53 tables, 54 figures and 195 Pages.

DMI Opinion:

The global diabetic ketoacidosis market is going to see moderate growth in upcoming years owing to rising usage of insulin therapy for diabetic ketoacidosis. Several researches are taking place worldwide for insulin therapy development. Numerous advances are taking place leading to the growth of market such as novel electrolyte replacement therapy. According to DMI the diabetic ketoacidosis market will see a decent growth with several novel therapies in the market.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development by the Researchers
      • 4.1.1.2. Rising Prevalence of Diabetic Ketoacidosis
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Diabetic Ketoacidosis Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Strategic Initiatives by Government and NGOs
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Pediatric Diabetic Ketoacidosis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adult Diabetic Ketoacidosis

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Insulin Therapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Electrolyte Replacement
    • 8.3.1. Potassium
    • 8.3.2. Magnesium
    • 8.3.3. Bicarbonate
    • 8.3.4. Phosphate
  • 8.4. Fluid Replacement

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Academic & Research Institutes
  • 9.4. Specialty Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.4.1. Brazil
      • 12.4.4.2. Argentina
      • 12.4.4.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novo Nordisk A/S *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Baxter Healthcare Corporation
  • 12.3. B. Braun Medical Inc.
  • 12.4. ICU Medical, Inc.
  • 12.5. Pfizer Inc.
  • 12.6. Merit Pharmaceutical
  • 12.7. SteriCare Solutions
  • 12.8. Soxa Formulations & Research(Pvt.) Ltd
  • 12.9. BD
  • 12.10. Fresenius Kabi USA

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us